60 related articles for article (PubMed ID: 19538231)
1. Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone.
Park SE; Kang ES; Kim DH; Kim SK; Lee JH; Ahn CW; Lee HC; Cha BS
Diabet Med; 2009 Jun; 26(6):577-81. PubMed ID: 19538231
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
4. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
5. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A
Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
[TBL] [Abstract][Full Text] [Related]
6. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
Shargorodsky M; Michaelova K; Boaz M; Gavish D; Zimlichman R
Diabet Med; 2007 Nov; 24(11):1254-60. PubMed ID: 17725634
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
Shetty C; Balasubramani M; Capps N; Milles J; Ramachandran S
Diabet Med; 2007 Jan; 24(1):94-7. PubMed ID: 17227331
[TBL] [Abstract][Full Text] [Related]
8. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
9. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes.
Kang ES; Park SY; Kim HJ; Kim CS; Ahn CW; Cha BS; Lim SK; Nam CM; Lee HC
Clin Pharmacol Ther; 2005 Aug; 78(2):202-8. PubMed ID: 16084854
[TBL] [Abstract][Full Text] [Related]
10. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
[TBL] [Abstract][Full Text] [Related]
12. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
Peters Harmel AL; Kendall DM; Buse JB; Boyle PJ; Marchetti A; Lau H
Curr Med Res Opin; 2004; 20(2):215-23. PubMed ID: 15006017
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
14. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients.
van Wijk J; Coll B; Cabezas MC; Koning E; Camps J; Mackness B; Joven J
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1134-7. PubMed ID: 17184491
[TBL] [Abstract][Full Text] [Related]
16. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.
Gutschi LM; Malcolm JC; Favreau CM; Ooi TC
Ann Pharmacother; 2006 Sep; 40(9):1672-6. PubMed ID: 16912247
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
[TBL] [Abstract][Full Text] [Related]
18. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
[TBL] [Abstract][Full Text] [Related]
19. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
20. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]